BioConsortia
Davis
About BioConsortia
BioConsortia is developing highly effective microbial consortia for increasing agricultural yields. Soil and plant-associated microbes interact with and supplement the functions encoded by the crop genome. Opportunities abound to exploit these plant-microbe interactions but overwhelming complexity and the huge amount of genetic diversity have hindered the realization of these by conventional R&D methods. BioConsortia has developed a revolutionary Advanced Microbial Selection (AMS) process for crop trait enhancement that uses iterative rounds of plant phenotyping and selection to co-select for beneficial changes in the microbiome. Isolates are obtained from the microbiome of plants expressing the desired traits and are developed as consortia for application as a commercial seed treatment, drench, or granule product. We have a pipeline of products for increased fertilizer utilization, growth improvement, and other beneficial crop traits, such as abiotic tolerance and enhanced metabolite expression.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $82.0M
- Last round: Series Unknown (Aug 2025)
- Website: bioconsortia.com
- Phone: 530-564 5570
Industries & Categories
Agriculture, AgTech, Biotechnology, Farming
Social Profiles
Canonical: https://fsome.com/organization/bioconsortia-96771 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.